Bioasis has entered into a research collaboration with Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis’ xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.
“The unique delivery method of the xB3TM platform has the potential to overcome a significant challenge in the treatment of brain disorders, which is the ability to cross the blood-brain barrier. Our xB3TM BBB drug delivery platform has the potential to significantly advance the treatment of disease, solving a major unmet clinical need and improving the lives of patients,” said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair.